StockNews.AI
MDAI
StockNews.AI
4 hrs

DeepView® System highlighted at the European Burns Association Congress

1. MDAI played a key role at the EBA conference in Berlin. 2. DeepView technology showcased significant advancements in burn care assessment. 3. Positive feedback from physicians indicates strong interest in DeepView System. 4. MDAI aims for global market expansion with its predictive burn wound system. 5. Research presentations at EBA highlight the technology's effectiveness in clinical settings.

7m saved
Insight
Article

FAQ

Why Bullish?

MDAI's prominent position at the EBA conference boosts visibility and market interest. Past instances show similar showcases led to positive stock reactions.

How important is it?

The advancements showcased at EBA directly tie into MDAI's growth strategy, making it highly relevant.

Why Long Term?

The ongoing research and adoption of the DeepView System can lead to sustained revenue growth. Long-term trends indicate increasing demand for AI in healthcare.

Related Companies

AIAMZNMDGL
DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the European Burns Association (EBA) conference, held from September 3rd – 6th in Berlin, Germany. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe. Key Presentations and Posters at EBA: Multispectral Imaging and Assessment of Burns Healing Potential: A Prospective Real-World Study to assess the DeepView Snapshot Imaging Platform – Sam Snelling, North Bristol NHS Trust, Bristol, United KingdomThe First Reader Study of Burn Wounds with Predictive Artificial Intelligence Analysis – Victoria Miles, Louisiana State University Health and Science Center, New Orleans, USArtificial Intelligence-Enhanced Multispectral Imaging for Burn Wound Assessment: Insights from a Multi-Centre UK Trial – Mr. Leslie Poh Hong Tan, Royal Victoria Infirmary, Newcastle, United KingdomEarly Experiences of the DeepView System wound imaging technology in a UK regional burn centre – Megan Beese, Queens Elizabeth Hospital, Birmingham, United KingdomPatient Experience of Using Artificial Intelligence-Enhanced Multispectral Imaging to Measure Burn Depth: A Regional Burns Centre Review – Miriam Nyeko-Lacek, Manchester University NHS Foundation Trust, United KingdomPreliminary Experience Using Artificial Intelligence and Multispectral Imaging for Burn Depth Assessment – Nicholas Solanki, Burns Unit Royal Adelaide Hospital, Adelaide, Australia Mr. Chris Lewis, Consultant Burn and Plastic Surgeon from Royal Victory Infirmary in Newcastle, said “With multiple presentations and posters from my team, colleagues and fellow users of DeepView in the United Kingdom, I was excited to see the results of their research and the interest by the European Burn Specialists. Our institution, as an early adopter, continues to use and see the value of the DeepView technology and we look forward to continuing to develop research and share our findings.” The European Burns Association Congress is a non-profit forum uniting specialists, researchers, and allied professionals to share knowledge, advance research, and promote best practices in burn prevention and treatment across Europe. Dr. J. Michael DiMaio, Chairman of the Board of Spectral AI, expressed pride in the Company’s role at the conference: “I am pleased with the DeepView System’s reception and results from our initial placement in the United Kingdom. We continue to seek physician feedback and support to bring this advanced burn wound technology to the worldwide market.” About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com. Forward-Looking Statements Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.  Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.  For Media and Investor Relations, please contact: David KugelmanAtlanta Capital Partners LLC(866) 692-6847 Toll Free - U.S. & Canada(404) 281-8556 Mobile and WhatsAppEmail: dk@atlcp.com

Related News